Compare Stocks

Date Range: 

 Guided TherapeuticsMicron SolutionsADM Tronics UnlimitedStar EquityVaso
SymbolOTCMKTS:GTHPOTCMKTS:MICROTCMKTSMKTS:ADMTNASDAQ:STRROTCMKTS:VASO
Price Information
Current Price$0.78$3.30N/A$2.85$0.07
52 Week RangeN/AN/AN/AN/AN/A
MarketRank™
Overall Score0.30.30.30.10.9
Analysis Score0.00.00.00.00.0
Community Score0.00.00.00.02.5
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.70.00.8
Earnings & Valuation Score0.01.30.00.61.3
Analyst Ratings
Consensus RecommendationN/AN/AN/AN/AN/A
Consensus Price TargetN/AN/AN/AN/AN/A
% Upside from Price TargetN/AN/AN/AN/AN/A
Trade Information
Market Cap$10.31 million$10.90 million$7.10 million$14.03 million$12.97 million
Beta0.80.5-0.210.243.26
Average Volume16,0185,51320,727292,417306,500
Sales & Book Value
Annual Revenue$40,000.00$17.50 million$3.49 million$114.18 million$75.75 million
Price / Sales257.630.620.000.120.17
CashflowN/AN/AN/A$3.61 per share$0.01 per share
Price / CashN/AN/AN/A0.7910.11
Book Value($5.35) per share$0.76 per share$0.05 per share$10.30 per share$0.03 per share
Price / Book-0.144.340.000.282.33
Profitability
Net Income$-1,920,000.00$-2,140,000.00$-100,000.00$-4,630,000.00$40,000.00
EPSN/AN/AN/AN/AN/A
Trailing P/E RatioN/A23.570.00N/A3.50
Forward P/E RatioN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A2.26%-5.50%-5.32%3.01%
Return on Equity (ROE)-29.31%19.35%-5.37%-3.75%46.49%
Return on Assets (ROA)502.80%4.88%-3.36%-0.85%4.60%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.08%0.88%0.33%
Current Ratio0.15%N/A2.43%1.27%0.58%
Quick Ratio0.14%N/A2.06%0.91%0.54%
Ownership Information
Institutional Ownership PercentageN/AN/AN/A10.14%N/A
Insider Ownership Percentage76.29%26.10%73.00%12.49%43.98%
Miscellaneous
Employees682N/A636294
Shares Outstanding13.30 million3.30 million67.59 million4.92 million185.24 million
Next Earnings Date7/6/2021 (Estimated)5/21/2021 (Estimated)N/A5/14/2021 (Confirmed)6/3/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Vaso (OTCMKTS:VASO) Share Price Passes Above Two Hundred Day Moving Average of $0.08Vaso (OTCMKTS:VASO) Share Price Passes Above Two Hundred Day Moving Average of $0.08
americanbankingnews.com - May 7 at 12:50 AM
El vaso medio llenoEl vaso medio lleno
mundodeportivo.com - May 5 at 1:49 AM
Tamaño del mercado global de Vaso, análisis de costos de fabricación con proveedores clave de materias primasTamaño del mercado global de Vaso, análisis de costos de fabricación con proveedores clave de materias primas
heraldolamango.com - May 4 at 8:49 PM
Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year of 2020Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year of 2020
finance.yahoo.com - May 4 at 8:49 PM
Short Interest in Vaso Co. (OTCMKTS:VASO) Rises By 166.2%Short Interest in Vaso Co. (OTCMKTS:VASO) Rises By 166.2%
americanbankingnews.com - April 29 at 5:10 AM
Vaso (OTCMKTS:VASO) Share Price Passes Above 200-Day Moving Average of $0.08Vaso (OTCMKTS:VASO) Share Price Passes Above 200-Day Moving Average of $0.08
americanbankingnews.com - April 28 at 2:16 AM
Poloxamer 188 does not decrease vaso-occlusive episodes in sickle cell disease: JAMAPoloxamer 188 does not decrease vaso-occlusive episodes in sickle cell disease: JAMA
medicaldialogues.in - April 27 at 8:34 AM
Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.
physiciansweekly.com - April 22 at 8:55 AM
Poloxamer 188 Flops for Sickle Cell Disease PainPoloxamer 188 Flops for Sickle Cell Disease Pain
medpagetoday.com - April 20 at 6:58 PM
Poloxamer 188 not effective for acute management of vaso-occlusive episodes in patients with sickle cell diseasePoloxamer 188 not effective for acute management of vaso-occlusive episodes in patients with sickle cell disease
2minutemedicine.com - April 20 at 1:57 PM
Vaso Corporation Expects to Report 2020 Financial Results by April 30, 2021Vaso Corporation Expects to Report 2020 Financial Results by April 30, 2021
finance.yahoo.com - April 15 at 7:00 PM
At Least 4,000 Venezuelans In Charlotte Area Now Eligible For Temporary Protected StatusAt Least 4,000 Venezuelans In Charlotte Area Now Eligible For Temporary Protected Status
wfae.org - April 13 at 11:58 PM
The Best Patios in Dallas For Right Now!The Best Patios in Dallas For Right Now!
dmagazine.com - April 13 at 11:58 PM
Lo que pasará cuando el relleno sanitario La Pradera llene su vasoLo que pasará cuando el relleno sanitario La Pradera llene su vaso
elcolombiano.com - April 11 at 10:42 PM
Así funciona la unidad del Hospital Isabel Zendal para secuelas graves del Covid: "No podía sostener un vaso de agua"Así funciona la unidad del Hospital Isabel Zendal para secuelas graves del Covid: "No podía sostener un vaso de agua"
elmundo.es - April 11 at 10:42 PM
The bungled Assassination that led to World War IThe bungled Assassination that led to World War I
patch.com - March 26 at 11:16 PM
New shop in Norman to host grand opening, to offer traditional Mexican treats, gourmet shaved iceNew shop in Norman to host grand opening, to offer traditional Mexican treats, gourmet shaved ice
oudaily.com - March 25 at 12:14 PM
Belgium to spend €200,000 on psychological well-being of doctorsBelgium to spend €200,000 on psychological well-being of doctors
brusselstimes.com - March 23 at 2:21 PM
Non-invasive Blood Pressure Monitors Market Projected to Hit at a Strong CAGR Between Forecast Period 2020 - 2027 by ARCNon-invasive Blood Pressure Monitors Market Projected to Hit at a Strong CAGR Between Forecast Period 2020 - 2027 by ARC
marketwatch.com - March 23 at 4:20 AM
SemaThera Enters into a Research Collaboration and Exclusive License Agreement with RocheSemaThera Enters into a Research Collaboration and Exclusive License Agreement with Roche
finance.yahoo.com - March 22 at 1:17 PM
Los pubs británicos se esfuerzan por ver el vaso medio lleno pese al coronavirusLos pubs británicos se esfuerzan por ver el vaso medio lleno pese al coronavirus
infobae.com - March 21 at 9:19 AM
10 Best Points To Do In Tijuana, Baja The Golden State10 Best Points To Do In Tijuana, Baja The Golden State
networksasia.net - March 6 at 3:29 AM
This beloved Phoenix taco shop is moving. Heres why it became nearly impossible stayThis beloved Phoenix taco shop is moving. Here's why it became 'nearly impossible' stay
dispatch.com - March 5 at 5:28 PM
Imara Reports Full Year 2020 Financial Results and Business HighlightsImara Reports Full Year 2020 Financial Results and Business Highlights
finance.yahoo.com - March 5 at 7:24 AM
Correction of murine sickle cell disease by allogeneic haematopoietic cell transplantation with anti-3rd party veto cellsCorrection of murine sickle cell disease by allogeneic haematopoietic cell transplantation with anti-3rd party veto cells
nature.com - March 3 at 5:25 PM
DateCompanyBrokerageAction
(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.